SCHEDULE: Kaufman Acquires 5.9% Stake in Stereotaxis

Daniel Louis Kaufman has reported beneficial ownership of 5,956,714 shares, representing 5.9% of Stereotaxis, Inc.'s common stock, as of August 12, 2026.

Summary

• Daniel Louis Kaufman has filed a Schedule 13G, reporting beneficial ownership of 5,956,714 shares of Stereotaxis, Inc. common stock.
• This holding represents 5.9% of the company's outstanding common stock as of July 31, 2026.
• The filing indicates sole voting and sole dispositive power over these shares.
• The shares were acquired by the event date of August 12, 2026.
• The filing asserts that the securities were not acquired or held for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not controlling stake acquisition by an individual investor, with no immediate indication of aggressive action.

Positives

• Significant individual investor stake established, potentially signaling confidence in the company's future.
• The investor holds sole voting and dispositive power, indicating clear control over their investment decisions.
• The filing explicitly states the shares are not held for the purpose of influencing control, suggesting a passive investment approach.

Negatives

• No specific details are provided regarding the acquisition cost or the exact date of purchase, only the event date requiring the filing.
• The filing does not offer any strategic insights or future plans from the investor regarding their stake.

Risks

• While stated as not for control, a 5.9% stake is substantial and could be a precursor to future activism or a significant block in a takeover scenario.
• The lack of detail on the investor's strategy leaves open the possibility of future actions that could be disruptive or beneficial.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from the company. It only reflects the current ownership status of Daniel Louis Kaufman.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that significant individual investor filings like this Schedule 13G are common in the biotechnology and medical device sectors, where innovation can lead to substantial shifts in company value. Such filings often precede increased investor scrutiny or potential strategic moves.

Stakeholder Impact

• Shareholders: May see increased volatility or interest in the stock due to the significant stake held by a new major individual investor.
• Management: May need to consider the investor's potential influence or future engagement, even if stated as passive.

Next Steps

• Monitor future filings by Daniel Louis Kaufman for any changes in ownership or stated intentions.
• Observe Stereotaxis, Inc.'s stock performance and strategic announcements for potential reactions to this increased individual shareholder presence.

Key Dates

Keywords

Stereotaxis, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Shareholder